Search
FibroGen Ord Shs
KYNBAdd to Watchlist
6.850USD
-0.030-0.44%
Close 06/23, 16:00（ET）Quotes delayed by 15 min
27.73MMarket Cap
0.17P/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
2
analysts
Buy
Current Rating
43.000
Target Price
+525.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
177
Total
6
Median
8
Average
Company name
Ratings
Analysts
FibroGen Ord Shs
KYNB
2
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
36
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is FibroGen Ord Shs's expected revenue for the next quarter?
FibroGen Ord Shs's expected revenue is 1.22M.
How have FibroGen Ord ShsKYNB's recent earnings per share performed?
The market expectation was USD -3.76, while FibroGen Ord ShsKYNB's earnings per share (EPS) for the previous quarter was USD -3.51. EPS for the next quarter is expected at USD -3.27.
What is the analyst rating for FibroGen Ord Shs?
Based on the ratings of FibroGen Ord Shs's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
